Hutch, C
Clinical Evidence on GLP-1 Efficacy Across Approved Formulations Injectable GLP-1 receptor agonists demonstrate consistent weight reduction of 1522% body weight over 68 weeks in clinical trials, depending on dose and patient baseline metabolic factors
Some preliminary evidence suggests that meal distribution throughout the day may influence metabolic responses, though direct effects on GLP-1 secretion specifically require further research
According to the Rybelsus Summary of Product Characteristics (SmPC) published on the Electronic Medicines Compendium (EMC), oral bioavailability remains relatively low compared to the injectable form, and the tablet must be taken on an empty stomach with no more than half a glass of water (approximately 120 ml), with the patient remaining fasting for at least 30 minutes afterwards, to maximise absorption
Results: Berberine ameliorates glucose metabolism in db/db mice
Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals
